A trial to learn how safe AZD4512 is with and without other cancer drugs and how it works in the bodies of people with B-cell non-Hodgkin lymphoma (B-NHL)

You likely can't join if

• 1.Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression. Participants with a prior history of CNS localization of lymphoma who received treatment are eligible provided that there is no evidence of CNS involvement at study entry as documented by CSF cytology and/or brain MRI.
• 10.Prior/Concomitant Therapy - Received adoptive cellular therapy such as autologous or donor NK cell or T lymphocyte infusions [eg CAR-T cells]), or T-cell engager therapy, within 90 days prior to the first dose of study treatment. - Received any investigational drug chemotherapy, immunotherapy, immunosuppressant medication, medications or herbal supplements known to be strong inhibitors of CYP3A4 within 21 days (or 5 half-lives, whichever is shorter) prior to the first dose of study treatment. - Received radiation therapy with curative intent within 14 days prior to the first dose of study treatment. Localized palliative radiotherapy is permitted. - Received prior allogeneic HSCT, unless the transplant occurred > 180 days prior to the first scheduled dose and the participant has no active graft-versus-host disease requiring treatment and has been stable off immunosuppression for at least 2 months or received prior autologous HSCT unless the transplant occurred > 90 days prior to the first dose of study treatment and transplant-related toxicities are resolved to at least a Grade 1. - Received major surgery within 28 days prior to the first dose of study treatment. - Any concomitant medications known to prolong QTc and/or have a known risk for Torsades de Pointes within 21 days or 5 half-lives, whichever is longer prior to the first dose of AZD4512 through the end of DLT review period.
• 11. Previous dosing with AZD4512 in the present study or participants with a known hypersensitivity to AZD4512 or any of the excipients of the product.
• 12. For women-only – currently pregnant (confirmed with positive pregnancy test) or breast-feeding (including when breast-feeding is interrupted) or intend to become pregnant during the study period.
• 2. Unresolved non-hematological AEs ≥ Grade 2 NCI CTCAE V5.0 from prior anticancer therapy, except for: (a) Alopecia, Fatigue, Grade 2 Peripheral neuropathy (peripheral neuropathy ≥ Grade 3 will be excluded), Endocrine disorders that are controlled with replacement therapy, or Stable vitiligo.
• 3.Any severe and uncontrolled medical condition (eg, diabetes mellitus, any history of seizure, bleeding diathesis, hepatic failure, clinically significant liver disease including cirrhosis or hepatitis, unstable respiratory or cardiac conditions, active infection [bacterial, viral, fungal, or other infection]), any major infection that required hospitalization or treatment with IV or oral antimicrobials within 14 days of Day 1.